Ulrich Specks

List of Publications by Year
in descending order

245 papers	18,928 citations	12330 69 h-index	12946 131 g-index
252 all docs	252 docs citations	252 times ranked	9990 citing authors

#	Article	IF	Citations
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	27.0	2,275
2	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	27.0	682
3	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	27.0	611
4	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 622-631.	27.0	465
5	ANCA-associated vasculitis. Nature Reviews Disease Primers, 2020, 6, 71.	30.5	443
6	Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyâ€"associated vasculitis. Arthritis and Rheumatism, 2005, 52, 262-268.	6.7	423
7	Antineutrophil cytoplasmic antibodies. Arthritis and Rheumatism, 1998, 41, 1521-1537.	6.7	404
8	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
9	Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis. Chest, 2003, 124, 177-185.	0.8	383
10	Rituximab for Refractory Wegener's Granulomatosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 180-187.	5.6	379
11	Eosinophilic granulomatosis with polyangiitis (Churgâ€"Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	2.2	371
12	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis and Rheumatism, 2001, 44, 2836-2840.	6.7	362
13	Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nature Reviews Rheumatology, 2017, 13, 683-692.	8.0	302
14	Churg-Strauss syndrome. American Journal of Medicine, 2003, 115, 284-290.	1.5	282
15	Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Annals of Internal Medicine, 2005, 142, 620.	3.9	277
16	Anticytoplasmic Autoantibodies in the Diagnosis and Follow-Up of Wegener's Granulomatosis. Mayo Clinic Proceedings, 1989, 64, 28-36.	3.0	272
17	Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Tenâ€year experience at a single center. Arthritis and Rheumatism, 2012, 64, 3770-3778.	6.7	248
18	Rituximab Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2188-2198.	4.5	247

#	Article	IF	Citations
19	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. Annals of Internal Medicine, 2007, 147, 611.	3.9	234
20	ANCA Are Detectable in Nearly All Patients with Active Severe Wegenerâ€™s Granulomatosis. American Journal of Medicine, 2007, 120, 643.e9-643.e14.	1.5	228
21	ANCA-associated vasculitis â€" clinical utility of using ANCA specificity to classify patients. Nature Reviews Rheumatology, 2016, 12, 570-579.	8.0	219
22	Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.4	217
23	Integrin and Arg-Gly-Asp Dependence of Cell Adhesion to the Native and Unfolded Triple Helix of Collagen Type VI. Experimental Cell Research, 1993, 206, 167-176.	2.6	204
24	Cutaneous Wegener's granulomatosis: Clinical, histopathologic, and immunopathologic features of thirty patients. Journal of the American Academy of Dermatology, 1994, 31, 605-612.	1.2	203
25	Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis and Rheumatism, 2004, 50, 2954-2965.	6.7	203
26	Exostosin 1/Exostosin 2â€"Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1123-1136.	6.1	198
27	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases, 2016, 75, 1166-1169.	0.9	196
28	Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis and Rheumatism, 2006, 54, 1608-1618.	6.7	195
29	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism, 2005, 52, 2168-2178.	6.7	171
30	Pneumocystis Pneumonia in Patients Treated With Rituximab. Chest, 2013, 144, 258-265.	0.8	154
31	Diffuse alveolar hemorrhage syndromes. Current Opinion in Rheumatology, 2001, 13, 12-17.	4.3	147
32	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
33	Cocaine-Induced Midline Destructive Lesions. Medicine (United States), 2001, 80, 391-404.	1.0	138
34	Association of Granulomatosis With Polyangiitis (Wegener's) With HLAâ€"DPB1*04 and SEMA6A Gene Variants: Evidence From Genomeâ€Wide Analysis. Arthritis and Rheumatism, 2013, 65, 2457-2468.	6.7	138
35	BAFF is elevated in serum of patients with Wegener's granulomatosis. Journal of Autoimmunity, 2005, 25, 298-302.	6.5	137
36	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	6.1	137

#	Article	IF	Citations
37	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis and Rheumatology, 2016, 68, 1700-1710.	5.6	132
38	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	5.6	130
39	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the Rheumatic Diseases, 2014, 73, 1376-1379.	0.9	128
40	Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 905-919.	4.5	126
41	The Epidemiology of Antineutrophil Cytoplasmic Autoantibodyâ€"Associated Vasculitis in Olmsted County, Minnesota. Arthritis and Rheumatology, 2017, 69, 2338-2350.	5.6	126
42	Neutrophilâ€Related Gene Expression and Lowâ€Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 1922-1932.	5.6	116
43	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.9	109
44	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2016, 45, 475-482.	3.4	109
45	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2011, 70, 704-704.	0.9	106
46	Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis and Rheumatology, 2016, 68, 1467-1476.	5.6	94
47	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.9	93
48	Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrology Dialysis Transplantation, 2011, 26, 2865-2871.	0.7	92
49	Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvementâ€"A Prospective, Open-Label Pilot Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 445-453.	4.5	89
50	Pulmonary Involvement in Henoch-Schnlein Purpura. Mayo Clinic Proceedings, 2004, 79, 1151-1157.	3.0	87
51	Alpha₁â€antitrypsin deficiencyâ€"related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis and Rheumatism, 2010, 62, 3760-3767.	6.7	87
52	Cardiac Involvement in Granulomatosis with Polyangiitis. Journal of Rheumatology, 2015, 42, 1209-1212.	2.0	87
53	Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. Journal of Rheumatology, 2002, 29, 309-16.	2.0	87
54	Airway Involvement in Wegener's Granulomatosis. Rheumatic Disease Clinics of North America, 2007, 33, 755-775.	1.9	83

#	Article	IF	Citations
55	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
56	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2019, 143, 2170-2177.	2.9	82
57	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	5.8	79
58	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
59	Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. Journal of Rheumatology, 2008, 35, 2017-23.	2.0	78
60	Detection of Anti-Neutrophil Cytoplasmic Antibodies under Actual Clinical Testing Conditions. Clinical Immunology, 2002, 103, 196-203.	3.2	77
61	Pathogenesis of ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 481-493.	4.7	77
62	Sinonasal Osteocartilaginous Necrosis in Cocaine Abusers: Experience in 25 Patients. American Journal of Rhinology & Allergy, 2003, 17, 33-43.	2.2	76
63	Echocardiographic Findings in Patients With Wegener Granulomatosis. Mayo Clinic Proceedings, 2005, 80, 1435-1440.	3.0	75
64	Update on Diffuse Alveolar Hemorrhage and Pulmonary Vasculitis. Immunology and Allergy Clinics of North America, 2012, 32, 587-600.	1.9	75
65	Myeloperoxidaseâ€"Antineutrophil Cytoplasmic Antibody (ANCA)â€"Positive and ANCAâ€Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis and Rheumatology, 2016, 68, 2945-2952.	5.6	75
66	Capture-ELISA based on recombinant PR3 is sensitive for PR3â€"ANCA testing and allows detection of PR3 and PR3â€"ANCA/PR3 immunecomplexes. Journal of Immunological Methods, 1998, 211, 111-123.	1.4	74
67	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20736-20741.	7.1	74
68	Bronchoalveolar Lavage Fluid Angiotensin-converting Enzyme in Interstitial Lung Diseases. The American Review of Respiratory Disease, 1990, 141, 117-123.	2.9	73
69	Melanoma Antigen A4 Is Expressed in Nonâ€"Small Cell Lung Cancers and Promotes Apoptosis. Cancer Research, 2006, 66, 4693-4700.	0.9	73
70	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. Transplantation, 2011, 91, 1370-1375.	1.0	71
71	Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. Mayo Clinic Proceedings, 2018, 93, 597-606.	3.0	69
72	Pituitary Dysfunction in Granulomatosis With Polyangiitis: The Mayo Clinic Experience. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3988-3994.	3.6	68

#	Article	IF	Citations
73	Expression of Type VI Collagen mRNA During Wound Healing. Journal of Investigative Dermatology, 1993, 100, 329-334.	0.7	65
74	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials, 2017, 18, 112.	1.6	65
75	Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis and Rheumatism, 2001, 44, 463-468.	6.7	62
76	Outcome of Patients With Small-Vessel Vasculitis Admitted to a Medical ICU. Chest, 2007, 131, 972-976.	0.8	62
77	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2011, 63, 1777-1781.	3.4	60
78	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). Autoimmunity Reviews, 2013, 12, 501-505.	5.8	60
79	Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney International, 1994, 45, 1648-1656.	5.2	59
80	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2011, 63, 3988-3997.	6.7	59
81	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.7	59
82	Solid malignancies among etanerceptâ€treated patients with granulomatosis with polyangiitis (Wegener's): Longâ€term followup of a multicenter longitudinal cohort. Arthritis and Rheumatism, 2011, 63, 2495-2503.	6.7	58
83	Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Letters, 2005, 579, 5305-5312.	2.8	53
84	Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaineâ€induced midline destructive lesions. Arthritis and Rheumatism, 2008, 58, 1546-1551.	6.7	53
85	Pulmonary Necrotizing Granulomas of Unknown Cause. Chest, 2013, 144, 813-824.	0.8	53
86	Anti-Neutrophil Cytoplasmic Antibodies. Mayo Clinic Proceedings, 1994, 69, 1197-1198.	3.0	52
87	Successful Pregnancy and Delivery of a Healthy Newborn Despite Transplacental Transfer of Antimyeloperoxidase Antibodies From a Mother With Microscopic Polyangiitis. American Journal of Kidney Diseases, 2009, 54, 542-545.	1.9	52
88	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 251-257.	4.5	50
89	Assessment of healthâ€related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2012, 64, 273-279.	3.4	49
90	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	5.6	49

#	Article	IF	Citations
91	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis with Severe Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2688-2704.	6.1	48
92	Primary Antiphospholipid Syndromeâ€"Associated Diffuse Alveolar Hemorrhage. Arthritis Care and Research, 2014, 66, 301-310.	3.4	47
93	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. Journal of the American Society of Nephrology: JASN, 2022, 33, 1033-1044.	6.1	47
94	Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha3(VI) chain. FEBS Journal, 1994, 225, 573-580.	0.2	46
95	Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. FEBS Letters, 1996, 390, 265-270.	2.8	46
96	Long-Term Follow-up of Repair of External Nasal Deformities in Patients With Wegener???s Granulomatosis. Laryngoscope, 2002, 112, 731-737.	2.0	46
97	Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1069-1071.	5.6	46
98	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.7	46
99	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegenerâ€™s Granulomatosis. Journal of Rheumatology, 2011, 38, 1048-1054.	2.0	45
100	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3â€"Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 185-193.	5.6	45
101	Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. Clinical Immunology, 2003, 109, 330-337.	3.2	43
102	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis and Rheumatism, 2005, 52, 902-910.	6.7	43
103	Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Current Opinion in Rheumatology, 2012, 24, 15-23.	4.3	43
104	Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. FEBS Letters, 1997, 408, 187-190.	2.8	41
105	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	2.0	40
106	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2020, 35, 283-291.	0.7	40
107	Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. Journal of Autoimmunity, 2017, 84, 122-131.	6.5	40
108	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2013, 40, 674-683.	2.0	39

#	Article	IF	Citations
109	Role of Testing for Anticytoplasmic Autoantibodies in the Differential Diagnosis of Scleritis and Orbital Pseudotumor. Mayo Clinic Proceedings, 1990, 65, 1110-1117.	3.0	37
110	Cell adhesion to type-VI collagen. Biochemical Society Transactions, 1991, 19, 843-847.	3.4	36
111	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	5.6	36
112	Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegenerâ€™s autoantigen. Journal of Autoimmunity, 2010, 35, 299-308.	6.5	35
113	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). PLoS ONE, 2015, 10, e0121737.	2.5	35
114	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. Journal of Rheumatology, 2007, 34, 2446-50.	2.0	35
115	Pulmonaryâ€¦Henoch-SchÃ¶nlein Purpura. Mayo Clinic Proceedings, 2004, 79, 1151-1157.	3.0	34
116	Meningeal Involvement in Wegener Granulomatosis. Mayo Clinic Proceedings, 2000, 75, 856-859.	3.0	33
117	Metaâ€analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3463-3471.	6.7	33
118	Lung involvement in ANCA-associated vasculitis. Presse Medicale, 2020, 49, 104039.	1.9	33
119	The future of damage assessment in vasculitis. Journal of Rheumatology, 2007, 34, 1357-71.	2.0	33
120	Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology, 2019, 58, 1707-1709.	1.9	32
121	Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. Journal of Renal Injury Prevention, 2017, 6, 18-25.	0.2	32
122	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	2.0	32
123	Mapping of Conformational Epitopes on Human Proteinase 3, the Autoantigen of Wegenerâ€™s Granulomatosis. Journal of Immunology, 2010, 185, 387-399.	0.8	31
124	Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease. Pharmacological Reviews, 2016, 68, 603-630.	16.0	30
125	Does infection play a role in the pathogenesis of pulmonary vasculitis?. Seminars in Respiratory Infections, 2003, 18, 17-22.	1.3	29
126	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). Arthritis and Rheumatology, 2014, 66, 428-432.	5.6	28

#	Article	IF	Citations
127	What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Research, 2000, 2, 263.	2.0	27
128	Eosinophilic Granulomatosis With Polyangiitis. Chest, 2020, 157, 1086-1099.	0.8	26
129	ARE ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES PATHOGENIC?. Rheumatic Disease Clinics of North America, 2001, 27, 815-832.	1.9	25
130	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 535-544.	5.6	25
131	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	5.6	25
132	Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2022, 37, 1710-1721.	0.7	25
133	Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. Journal of Immunological Methods, 2000, 244, 117-131.	1.4	24
134	Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. Kidney International, 2003, 63, 756-760.	5.2	24
135	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical Chemistry, 2016, 88, 6317-6325.	6.5	24
136	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Autoimmunity, 2019, 105, 102302.	6.5	24
137	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research, 2017, 19, e50.	4.3	24
138	A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. Journal of Immunological Methods, 2005, 307, 62-72.	1.4	23
139	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1879-1887.	5.6	23
140	Methotrexate for Wegener's granulomatosis: What is the evidence?. Arthritis and Rheumatism, 2005, 52, 2237-2242.	6.7	22
141	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. Journal of Rheumatology, 2007, 34, 1027-31.	2.0	22
142	Clinical utility of ANCA tests for the dermatologist. International Journal of Dermatology, 2003, 42, 859-869.	1.0	21
143	Pulmonary Capillaritis. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 547-555.	2.1	21
144	A Monoclonal Antibody (MCPR3-7) Interfering with the Activity of Proteinase 3 by an Allosteric Mechanism. Journal of Biological Chemistry, 2013, 288, 26635-26648.	3.4	21

#	Article	IF	Citations
145	Accurate Relapse Prediction in ANCA-Associated Vasculitisâ€"the Search for the Holy Grail. Journal of the American Society of Nephrology: JASN, 2015, 26, 505-507.	6.1	21
146	The Pharmacogenomic Association of FcÎ³ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 169-175.	5.6	21
147	Clinical Manifestations and Longâ€Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	2.1	21
148	Lesions of the Respiratory Tract Associated With the Finding of Anti-Neutrophil Cytoplasmic Autoantibodies With a Perinuclear Staining Pattern. Mayo Clinic Proceedings, 1994, 69, 819-824.	3.0	20
149	Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. Respirology, 2016, 21, 734-738.	2.3	20
150	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	1.9	20
151	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. Journal of Rheumatology, 2020, 47, 1001-1010.	2.0	20
152	Are animal models of vasculitis suitable tools?. Current Opinion in Rheumatology, 2000, 12, 11-19.	4.3	19
153	Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. Clinics in Chest Medicine, 2019, 40, 573-582.	2.1	19
154	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. Frontiers in Immunology, 2022, 13, 834981.	4.8	19
155	Wegener's granulomatosis presenting as multiple bilateral renal masses. Nephrology Dialysis Transplantation, 2004, 19, 984-987.	0.7	18
156	Coexistent Pulmonary Granulomatosis With Polyangiitis (Wegener Granulomatosis) and Crohn Disease. American Journal of Surgical Pathology, 2014, 38, 354-359.	3.7	18
157	Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respiratory Medicine, 2018, 142, 66-72.	2.9	18
158	Isolated Pauciimmune Pulmonary Capillaritis Successfully Treated With Rituximab. Chest, 2015, 147, e134-e136.	0.8	17
159	Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial. Open Arthritis Journal, 2011, 4, 1-18.	0.0	17
160	Functional Significance of Asn-linked Glycosylation of Proteinase 3 for Enzymatic Activity, Processing, Targeting, and Recognition by Anti-neutrophil Cytoplasmic Antibodies. Journal of Biochemistry, 2006, 141, 101-112.	1.7	16
161	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. PLoS ONE, 2012, 7, e30197.	2.5	16
162	Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. Clinical Rheumatology, 2020, 39, 1581-1590.	2.2	16

#	Article	IF	Citations
163	The Growing Complexity of the Pathology Associated With Cocaine Use. Journal of Clinical Rheumatology, 2011, 17, 167-168.	0.9	15
164	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. American Journal of Nephrology, 2017, 46, 231-238.	3.1	15
165	Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. American Journal of Rhinology & Allergy, 2003, 17, 33-43.	2.2	14
166	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 114-118.	0.8	14
167	Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?. Nephrology Dialysis Transplantation, 2015, 30, 1083-1087.	0.7	13
168	Association of <scp>COVID</scp>â€19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis. Respirology Case Reports, 2022, 10, e0894.	0.6	13
169	Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. Rheumatic Disease Clinics of North America, 2007, 33, 741-754.	1.9	12
170	Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clinical and Experimental Immunology, 2017, 188, 174-181.	2.6	12
171	Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrology Dialysis Transplantation, 2017, 32, gfw384.	0.7	12
172	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2018, 70, 2077-2086.	5.6	12
173	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clinical Pharmacokinetics, 2020, 59, 519-530.	3.5	12
174	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Frontiers in Immunology, 2020, 11, 2053.	4.8	12
175	Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrology Dialysis Transplantation, 2021, 36, 231-236.	0.7	12
176	A 70-Year-Old Man With Pulmonary Infiltrates and a Positive Antineutrophil Cytoplasmic Autoantibody Test Result. Chest, 2005, 127, 1045-1050.	0.8	11
177	Accuracy of the ICD-9 Code for Identification of Patients with Wegenerâ€™s Granulomatosis: Table 1. Journal of Rheumatology, 2010, 37, 474-474.	2.0	11
178	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis Care and Research, 2017, 69, 1004-1010.	3.4	11
179	Controversies in ANCA testing. Cleveland Clinic Journal of Medicine, 2012, 79, S7-S11.	1.3	11
180	Echocardiographic features of atrial myocarditis with giant cells: A case report. Journal of the American Society of Echocardiography, 2004, 17, 1073-1076.	2.8	10

#	Article	IF	Citations
181	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 816-816.	5.6	9
182	TNF-Î± Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 501-508.	4.7	9
183	ANCA subsets: influence on disease phenotype.. Cleveland Clinic Journal of Medicine, 2002, 69, SII56-SII56.	1.3	9
184	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 58-74.	2.7	8
185	Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?. Current Opinion in Rheumatology, 2015, 27, 231-240.	4.3	8
186	Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. International Forum of Allergy and Rhinology, 2020, 10, 217-222.	2.8	8
187	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Chest, 2021, 160, 572-581.	0.8	8
188	Microtiter plate immunoassay for the evaluation of platelet adhesion to fibronectin. Journal of Immunological Methods, 1996, 191, 55-63.	1.4	7
189	Will LAMP enlighten us about ANCA-associated vasculitis?. Nature Reviews Nephrology, 2012, 8, 318-320.	9.6	7
190	Remote Activation of a Latent Epitope in an Autoantigen Decoded With Simulated B-Factors. Frontiers in Immunology, 2019, 10, 2467.	4.8	7
191	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. American Journal of Pathology, 2020, 190, 1438-1448.	3.8	7
192	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	5.0	7
193	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 40-44.	0.8	7
194	Epitopeâ€specific antiâ€neutrophil cytoplasmic antibodies: Do they matter? Can they be detected?. Apmis, 2009, 117, 63-66.	2.0	6
195	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease, 2014, 21, 182-193.	1.4	6
196	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. Journal of Autoimmunity, 2015, 59, 43-52.	6.5	6
197	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	2.5	6
198	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6

#	Article	IF	Citations
199	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight, 2020, 5, .	5.0	6
200	Biologic agents in the treatment of granulomatosis with polyangiitis. Cleveland Clinic Journal of Medicine, 2012, 79, S50-S53.	1.3	6
201	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with <scp>ANCAâ€Associated</scp> Vasculitis. ACR Open Rheumatology, 2022, 4, 168-176.	2.1	6
202	S1. Rituximab for ANCA-associated vasculitis: The experience in the United States. Presse Medicale, 2013, 42, 530-532.	1.9	5
203	Refining phenotypes in ANCA-associated vasculitis. Nature Reviews Nephrology, 2013, 9, 6-8.	9.6	5
204	Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis. Current Treatment Options in Rheumatology, 2017, 3, 193-206.	1.4	5
205	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. Clinical Pharmacokinetics, 2022, 61, 423-437.	3.5	5
206	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. Journal of the American Society of Nephrology: JASN, 2022, 33, 1223-1224.	6.1	5
207	Reply: Further Progress in Understanding Fibrosing Mediastinitis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 768-768.	5.6	3
208	The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibodyâ€"associated Vasculitis. Journal of Rheumatology, 2019, 46, 1243-1243.	2.0	3
209	Interstitial Lung Disease and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Chest, 2021, 159, 2141-2142.	0.8	3
210	Granulomatosis with Polyangiitis (Wegener's). , 0, , 238-251.		3
211	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 98-101.	0.8	3
212	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 114-118.	0.8	3
213	Acquired cyclic neutropenia associated with cocaineâ€induced antiâ€neutrophil cytoplasmic antibodies binding to human neutrophil elastase. American Journal of Hematology, 2018, 93, E227-E229.	4.1	2
214	Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Journal of Clinical Rheumatology, 2021, 27, 64-72.	0.9	2
215	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	1.9	2
216	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	1.4	2

#	Article	IF	Citations
217	A Rare Cause Hemoptysis Illustrating the Role of Single Ventricle Physiology in Bronchial Circulatio. Chest, 2011, 140, 83A.	0.8	1
218	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 1081-1082.	0.7	1
219	PREVALENCE OF PLEURITIS AND PERICARDITIS IN ANCA-ASSOCIATED VASCULITIS. Chest, 2018, 154, 1019A-1020A.	0.8	1
220	Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjÃ¶gren syndrome. Respiratory Medicine Case Reports, 2021, 33, 101432.	0.4	1
221	Pulmonary Vasculitis. , 2012, , 365-386.		1
222	Clinical role of C-ANCA testing. Clinical Immunology Newsletter, 1990, 10, 171-174.	0.1	0
223	Wegener??s Granulomatosis and Pulmonary Vasculitis. Clinical Pulmonary Medicine, 1995, 2, 267-275.	0.3	0
224	Tumor necrosis factor ? blockade as therapy for sarcoidosis: Comment on the article by Ulbricht et al. Arthritis and Rheumatism, 2004, 50, 2717-2718.	6.7	0
225	Subtle modifications of a PR3-ANCA ELISA affect assay performance. Clinical Immunology, 2006, 118, 124-125.	3.2	0
226	A REVIEW OF NECROTIZING GRANULOMAS. Chest, 2007, 132, 639A.	0.8	0
227	55-Year-Old Man With Purpura and Foot Pain. Mayo Clinic Proceedings, 2008, 83, 93-96.	3.0	0
228	Response to â€˜Rituximab in membranous nephropathyâ€™. Kidney International, 2008, 74, 392.	5.2	0
229	Pulmonary Vasculitis and Hemorrhage. , 2012, , 722-730.		0
230	Biologic response modifiers for granulomatosis with polyangiitis (Wegenerâ€™s): from promise to reality. International Journal of Clinical Rheumatology, 2013, 8, 383-397.	0.3	0
231	Reply. Arthritis and Rheumatology, 2016, 68, 2828-2829.	5.6	0
232	Advances in Management of Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis. Chest, 2016, 150, 536A.	0.8	0
233	Reply. Arthritis and Rheumatology, 2017, 69, 1507-1508.	5.6	0
234	172.â€ƒTHE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV). Rheumatology, 2019, 58, .	1.9	0

#	Article	IF	Citations
235	053.â€ƒCLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	1.9	0
236	THU0309â€…NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS. , 2019, , .		0
237	SAT0012â€…DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
238	SAT0236â€…RELATIONSHIP BETWEEN RITUXIMAB CONCENTRATION AND AUTOANTIBODY LEVELS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS. , 2019, , .		0
239	Remission maintenance in ANCA-associated vasculitis: does one size fit all?. Expert Review of Clinical Immunology, 2019, 15, 1273-1286.	3.0	0
240	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. Rheumatology, 2020, 59, 1187-1187.	1.9	0
241	The Survival of Patients With Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. Journal of Rheumatology, 2021, 48, 314-317.	2.0	0
242	Vasculitis and Alveolar Hemorrhage. , 2022, , 341-357.		0
243	ANCA-Associated Vasculitis. , 2009, , 245-267.		0
244	Pathogenesis and Management of ANCA-Associated Vasculitis. , 2014, , 137-151.		0
245	Pulmonary Manifestations of Vasculitis. , 2014, , 123-137.		0